DaVita investigated by Justice
This article was originally published in The Gray Sheet
Executive Summary
Dialysis services firm will provide documents relating to medical director compensation, joint venture agreements with physicians and drug services to DoJ under a March 4 subpoena. The U.S. Attorney for the Eastern District of Missouri's investigation "significantly overlaps" with a similar action begun in February 2001 by the U.S. attorney in Philadelphia, the firm notes. DaVita acquisition target Gambro settled similar issues with the St. Louis attorney's office in December 2004 (1"The Gray Sheet" Dec. 13, 2004, p. 12)...
You may also be interested in...
Gambro Sale Of U.S. Dialysis Services Leaves $2 Bil. For Possible Acquisitions
Gambro's plan to refocus on its core renal and blood bank product offerings by divesting its U.S. dialysis services business provides about $2 bil. for potential acquisitions in related fields
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.